Tetrahydroxystilbene glucoside / TGF-β Cancer Research Results

TSG, Tetrahydroxystilbene glucoside: Click to Expand ⟱
Features:

Tetrahydroxystilbene glucoside (TSG; 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside) is an isolated stilbene glycoside and a major bioactive constituent of Polygonum multiflorum Thunb. TSG has antioxidant, anti-inflammatory, mitochondrial-protective, neuroprotective and cardiovascular effects in preclinical studies. In Alzheimer-related models, it has reduced amyloid-β toxicity and microglial activation, supported synaptic plasticity, protected against mitochondrial dysfunction and improved learning or memory outcomes. Alternative names include THSG, PM-SG and tetrahydroxystilbene glucoside.



TGF-β, transforming growth factor-beta: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-CS TCGA
Type:
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses.
Anti-inflammatory cytokine.
In normal tissues, TGF-β plays an essential role in cell cycle regulation, immune function, and tissue remodeling.
- In early carcinogenesis, TGF-β typically acts as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis.

In advanced cancers, cells frequently become resistant to the growth-inhibitory effects of TGF-β.
- TGF-β then switches roles and promotes tumor progression by stimulating epithelial-to-mesenchymal transition (EMT), cell invasion, metastasis, and immune evasion.

Non-canonical (Smad-independent) pathways, such as MAPK, PI3K/Akt, and Rho signaling, also contribute to TGF-β-mediated responses.

Elevated levels of TGF-β have been detected in many advanced-stage cancers, including breast, lung, colorectal, pancreatic, and prostate cancers.
 - The switch from a tumor-suppressive to a tumor-promoting role is often associated with increased TGF-β production and activation in the tumor microenvironment.

High TGF-β expression or signaling activity is frequently correlated with aggressive disease features, resistance to therapy, increased metastasis, and poorer overall survival in many cancer types.
Scientific Papers found: Click to Expand⟱
7045- EMD,  TSG,    Synergic effects and possible mechanism of emodin and stilbene glycosides on colorectal cancer
- vitro+vivo, CRC, NA
Apoptosis↑, TumCMig↓, TumVol↓, IL6↓, TGF-β↓, i-P53↓, i-STAT3↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

i-P53↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

i-STAT3↓, 1,  

Migration(tgid=13) ⓘ

TGF-β↓, 1,   TumCMig↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

TumVol↓, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TGF-β, transforming growth factor-beta
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:428  Target#:304  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page